key: cord-1018610-d9ullqkp
authors: Rayner-Hartley, Erin; Miller, P. Elliott; Burstein, Barry; Bibas, Lior; Goldfarb, Michael; Rampersad, Penelope; van Diepen, Sean
title: The Basics of ARDS Mechanical Ventilatory Care for Cardiovascular Specialists
date: 2020-07-23
journal: Can J Cardiol
DOI: 10.1016/j.cjca.2020.07.011
sha: 52eceff4a4afdf01b622adf9a1601c4e487c234b
doc_id: 1018610
cord_uid: d9ullqkp

The ongoing coronavirus disease 2019 (COVID-19) pandemic has placed pressure on healthcare systems and intensive care unit capacity worldwide. Respiratory insufficiency is the most common reason for hospital admission in patients with COVID-19. The most severe form of respiratory failure is acute respiratory distress syndrome (ARDS), which is associated with significant morbidity and mortality. Patients with ARDS are often treated with invasive mechanical ventilation according to established evidence-based and guideline recommended management strategies. With growing strain on critical care capacity, clinicians from diverse backgrounds, including cardiovascular specialists, may be required to help care for the growing number of patients with severe respiratory failure and ARDS. The aim of this article is to outline the fundamentals of ARDS diagnosis and management, including mechanical ventilation (MV), for the non-intensivist. In the absence of MV trials specifically in COVID-19 associated ARDS, the information presented is based on general ARDS trials.

The acute respiratory distress syndrome (ARDS) is a serious condition with significant morbidity and mortality. During the current COVID-19 pandemic, non-intensivists, including cardiovascular specialists, may be called upon to help manage critically ill patients with ARDS. This article aims to provide a concise and pragmatic review of the diagnosis and management of ARDS, with a focus on the basic principles of safe mechanical ventilation which can be applied to patients with respiratory failure including those with COVID-19.

The outbreak of a novel coronavirus disease 2019 (COVID-19) has spread globally since it was first reported in December 2019. Although a variety of clinical manifestations have been reported, the primary reason for morbidity and mortality is hypoxemic respiratory failure (1) . Among hospitalized patients, the published mortality is approximately 5% and is commonly due to refractory respiratory failure and shock (1) .

Epidemiological studies report that acute respiratory distress syndrome (ARDS) is common among hospitalized patients with COVID-19 and represents the primary indication for transfer to intensive care units (ICU) (1) . Recently published guidelines summarize the current recommendations in this rapidly evolving field (2) . As healthcare systems become increasingly strained, patients with COVID-19 have been admitted to clinical environments where teams and physicians have less experience with ARDS management. This article is intended to provide a pragmatic guide for non-intensivist practitioners caring for patients with ARDS requiring mechanical ventilation (MV). In the absence of MV trials specifically in COVID-19 associated ARDS, the information presented is based on general ARDS trials. We encourage readers to supplement this paper with the evolving literature on management of COVID-19 specific ARDS.

The Berlin definition of ARDS requires all of the following criteria to be present: 1) symptoms or known clinical insult within one week; 2) bilateral opacities on chest imaging, not fully explained by effusions, nodules, or atelectasis; 3) respiratory failure not fully explained by cardiac failure or hypervolemia; 4) PaO 2 /FiO 2 ≤ 300 with positive end expiratory pressure (PEEP) ≥ 5 cm H 2 O. ARDS is further classified by severity based on arterial blood gas analysis: mild (PaO 2 /FiO 2 201-300), moderate (PaO 2 /FiO 2 101-200), and severe (PaO 2 /FiO 2 ≤ 100) (3) . ARDS is commonly associated with various infectious, traumatic, and inflammatory conditions, all of which are associated with direct and indirect lung injury; however, a clear pathophysiological mechanism has not been elucidated. Importantly, many patients with these associated conditions will not develop ARDS, suggesting that other pathophysiological mechanisms may play an inciting role. Cardiovascular specialists should be aware of ARDS mimickers, such as heart failure and alveolar hemorrhage.

Advances in supportive strategies, including MV with invasive positive pressure ventilation via endotracheal intubation, have improved outcomes for patients with ARDS; however, mortality remains high. Death may result as a consequence of the underlying illness, refractory hypoxia with or without progressive right ventricular dysfunction, due to multiple organ failure, and/or critical illness complications.

Although a detailed review of respiratory and MV physiology is beyond the scope of this manuscript, a working understanding of a basic MV pressure waveform is required to understand the stepwise algorithm presented below. MV breaths are delivered in either a spontaneous or mandatory mode. In a mandatory mode, the ventilator delivers a set number of breaths per minute, defined as the respiratory rate (RR), regardless of patient effort. These delivered breaths are either volume controlled (VC) whereby a set tidal volume (V T ) is delivered, or pressure controlled (PC) whereby a set inspiratory pressure is delivered. A mandatory VC pressure waveform is presented in Figure 1 . The peak pressure is the highest pressure reached during the respiratory cycle and represents both alveolar pressure and resistance to air flow. The plateau pressure is measured during an inspiratory hold, and as such, represents alveolar pressure alone without a resistance component. Isolated high peak pressures can be seen with high resistance in the circuit, bronchospasm, secretions or endotracheal tube obstruction. High peak and plateau pressures can be seen in parenchymal lung disease (pulmonary edema, ARDS, consolidation, pneumothorax) or secondary to extrapulmonary causes such as pleural effusions, intraabdominal hypertension and morbid obesity ( Figure S1 ).

Following inspiration to the peak inspiratory pressure, expiration begins with a predetermined termination signal (flow or pressure) and is characterized by exponential decrease in airway pressure back to the set PEEP. PEEP improves oxygenation, in part, by mitigating alveolar collapse and increasing the surface area for gas exchange at the alveolar level. The driving pressure is a measure of 'lung shear stress' (or cyclical lung strain) and is calculated by subtracting the plateau pressure from the total PEEP.

An algorithmic approach to managing MV in ARDS patients is provided in Figure   2 and the evidence underpinning these recommendations is outlined in Table S1 in Supplementary Materials. When initiating low tidal volume ventilation (LTVV), the first decision involves choosing the mode of MV. VC will deliver a consistent V T and is a reasonable initial choice. Additionally, VC provides the option of setting a 0.2 second inspiratory hold, which gives a real-time plateau pressure measurement. Next, the V T and RR are set, which together determine the total minute ventilation and, therefore, CO 2 clearance and pH. We suggest using 6 mL/kg predicted body weight (PBW) V T as an initial setting. The RR is set to meet the patient's minute ventilatory demands while allowing for permissive hypercapnia (ie pH 7.25-7.35 and PaCO 2 > 45 mmHg). It is reasonable to set the initial RR at 20 breathes per minute and subsequently adjust it to maintain an arterial pH > 7.25. We suggest setting an initial PEEP of 10 cmH 2 0 and FiO 2 of 1.0. We suggest weaning the FiO 2 as soon as possible to target a SpO2 of 88 -95% or a PaO2 of 55 -80 mmHg.

Following MV initiation, the PEEP and FiO 2 can be adjusted using the ARDSNet PEEP table in Figure 2 . We favour the low PEEP table as the initial strategy as routine higher PEEP strategies have not been associated with improved outcomes. Importantly however, lung injury is often heterogeneous, and clinicians must individualize MV settings accordingly. 

Most patients will be adequately managed with the aforementioned ARDS MV management principles; however, some patients may require advanced treatment for refractory hypoxemia or hypercapnia (Table S1 ). These patients should be managed in collaboration with a Critical Care Medicine specialist. It is important to acknowledge that the therapies discussed in this section have not been definitively shown to improve mortality. Continuous neuromuscular blockade (NMB) has the potential benefit of reducing patient-ventilator dyssynchrony and/or work of breathing in patients with ARDS; however, the efficacy of routine NMB in ARDS in randomized trials is conflicting (5 , Table S1 ). Given the potential adverse consequences of NMB, such as ICU weakness, we do not routinely use this in our practice. Indications to consider NMB If patients continue to have refractory hypoxemia or hypercapnia, a consultation for veno-venous ECMO, depending on regional local availability and patient candidacy, can be considered. The Murray score is composed of four variables (hypoxemia, respiratory compliance, chest x-ray findings and PEEP) and is used to grade the severity of lung injury in ARDS. A Murray score > 3.0 or a pH < 7.20 -7.25 while on optimized therapy, should prompt early notification to the ECMO team.

Cardiovascular specialists who routinely care for patients requiring MV without ARDS are well positioned to care for critically ill patients. It is imperative that clinicians understand and feel comfortable with the basic management of ARDS, which can be applied to patients with respiratory failure due to COVID-19. 

Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-infected Pneumonia in Wuhan

Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)

An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome

Fluid management with a simplified conservative protocol for the acute respiratory distress syndrome

Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome

Funding Sources: none Disclosures: none